Market News AIOpen the app

Regeneron got the go-ahead from Europe for a new Libtayo dosing plan that cuts down on clinic visits and infusion times.

TrialRead the original at newsroom.regeneron.com
Good for REGN

The EU approval lets patients with covered cancers have fewer visits and shorter infusions, which may make Libtayo easier to use. The report gives no sales figures, but the approved convenience favors Regeneron.

REGN · Regeneron Pharmaceuticals, Inc.

AI read · Good for REGN

The AI's read

Fewer clinic visits and shorter infusions may make Libtayo easier for patients and care teams to use. That could help the treatment appeal to more people, but the report gives no sales or use figures.

Get alerts for REGN

Follow Regeneron Pharmaceuticals, Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for REGN
Free on the App Store and Google Play, or on the web.